Accepted Manuscript

Clinical Islet Xenotransplantation: A Step Forward

Burcin Ekser, Rita Bottino, David K.C. Cooper

PII: S2352-3964(16)30444-3
DOI: doi: 10.1016/j.ebiom.2016.09.023
Reference: EBIOM 796

To appear in: *EBioMedicine*

Received date: 21 September 2016
Accepted date: 21 September 2016

Please cite this article as: Ekser, Burcin, Bottino, Rita, Cooper, David K.C., Clinical Islet Xenotransplantation: A Step Forward, *EBioMedicine* (2016), doi: 10.1016/j.ebiom.2016.09.023

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CLINICAL ISLET XENOTRANSPLANTATION: A STEP FORWARD

Burcin Ekser, MD, PhD¹, Rita Bottino, PhD², David K.C. Cooper, MD, PhD³
(1) Transplant Division, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA; (2) Institute for Cellular Therapeutics, Allegheny-Singer Research Institute, Pittsburgh, PA, USA; (3) Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, USA

Address correspondence to:
Burcin Ekser, MD, PhD
Transplant Division, Department of Surgery
Indiana University School of Medicine
550 University Blvd, Room 4601
Indianapolis, IN, 46202
Telephone: 317-948-3835; Fax 317-948-3268
Email: bekser@iupui.edu

With the encouraging results of pancreatic islet allotransplantation, increasing attention is being directed towards pig islet xenotransplantation, which would resolve the problem of islet supply (Markmann et al 2016, Ekser et al 2012). Free (nonencapsulated) pig islets (either wild-type or genetically-engineered) have maintained normoglycemia in immunosuppressed diabetic nonhuman primates for >1 year (Park et al 2015). Immunoisolated (encapsulated) pig islets have maintained normoglycemia in non-immunosuppressed diabetic nonhuman primates for up to 6 months (Dufrane et al 2006).
Groth et al performed the first clinical islet xenotransplantation in 1994 using fetal porcine islet-like cell clusters placed under the kidney capsule (Groth et al 1994). Although clinical benefit was not demonstrated, evidence was provided by measurement of porcine C-peptide that porcine islets could survive in the human body. The first nationally-regulated clinical trial of intra-peritoneal alginate-poly-L-ornithine-alginate (APA) encapsulated (neonatal) porcine islet xenotransplantation in nonimmunosuppressed diabetic patients was carried out in New Zealand and was associated with some reduction in hypoglycemic unawareness (Matsumoto et al 2014). However, there was a lack of correlation between the number of islets transplanted and the clinical outcome; the transplantation of 5,000 IEq/kg was associated with better results than of 15,000 or 20,000 IEq/kg.

In this issue of EBioMedicine, Matsumoto et al report the second clinical trial of nationally-regulated encapsulated porcine islet xenotransplantation, conducted in Argentina (Matsumoto et al 2016). From their previous experience, the authors speculated that a large islet mass was susceptible to injury from oxygen and/or nutrient insufficiency, resulting in cell death. To avoid this problem, the islets were transplanted in two steps, with the second transplant being carried out 3 months after the first. In order to transplant a total of 10,000 IEq/kg or 20,000 IEq/kg, patients received either 5,000 IEq/kg x 2 (n=4) or 10,000 IEq/kg x 2 (n=4) of encapsulated neonatal porcine islets in their peritoneal cavity by laparoscopy.

Although the study demonstrated significant improvement in HbA1c and reduction of hypoglycemic unawareness events with an improved transplant estimated
function (TEF) score for up to 2 years post-transplant, the reduction of insulin dose was marginal or none. (Importantly, there was no evidence of complications from the transfer of porcine endogenous retroviruses.)

Although this second carefully-supervised trial is a step forward in the field of clinical islet xenotransplantation, several aspects need consideration before large-scale clinical trials will become justified (van der Windt et al. 2012).

(i) The number of islets obtained from the source pigs

Neonatal pigs may have some advantages as sources of islets (discussed by Nagaraju et al., 2015), one of which is their potential to proliferate after transplantation (which is not believed to be the case with adult islets). Whether there was any evidence that this occurred in the present study was not reported. However, it is reasonable to anticipate that ‘neonatal’ pigs (newborn to 5 days old) may provide a yield of up to 25,000 islets, and ‘young’ pigs (7-22 days old) may provide up to 30,000 islets. A 70kg patient would therefore require 700,000 islets (70 x 10,000 IE/kg) or, more likely, 1.4 million islets (70 x 20,000 IE/kg), indicating that a single patient would require islets from approximately 25-50 piglets. With 8-12 piglets in each litter, this would be feasible. If, however, there is confirmed evidence of proliferation of the islets after transplantation, the number of piglets required may be fewer.
(ii) *Encapsulation of pig islets and the immune response*

Although the great theoretical advantage of the transplantation of encapsulated islets is that exogenous immunosuppressive therapy may not be required, the long-term viability of the encapsulated islets remains questionable. The dilemma in APA-based encapsulated islets is that, if the islets are not revascularized, they are likely to become exhausted (and die) from lack of nutrients and oxygen, particularly as some fibrin accumulates around the capsules, possibly reducing their permeability. In contrast, if the islets are revascularized, they are likely to become susceptible to injury from an immune or inflammatory response. There is already evidence that APA-based microencapsulated porcine islets induce an inflammatory response, upregulating inflammatory cytokines and activating innate immune cells, such as tumor necrosis factor-α, IL-6, interferon-γ, macrophages, neutrophils, and dendritic cells (Cooper et al 2016). The great deficiency of the present study is that the authors did not investigate whether there was an immune response to the islets (or capsules), though they speculated that microcapsules might shed xeno-antigens which activate the recruitment of CD4+ T cells and macrophages around the capsule. It will be essential to determine whether there is an immune response to the pig islets. If there is, either modification of the capsules or the administration of exogenous immunosuppressive
therapy will be necessary, unless the islets can be completely protected by genetic manipulation of the pig.

Our own opinion is that it will be difficult to totally protect the encapsulated islets from the effects of cytokines and chemokines and possibly other components of the immune response, and therefore some immunosuppressive therapy may prove inevitable, thus negating the major theoretical advantage of ‘immunoisolation’. Nevertheless, as the number of pancreases from deceased humans that become available will never suffice to cure all patients with T1D, the pioneering studies by Matsumoto and his colleagues are important and timely.

Disclosure

The authors declared no conflicts of interest.
REFERENCES

Cooper, D.K, Matsumoto, S., Abalovich, A., et al. 2016. Progress in clinical encapsulated islet xenotransplantation. Transplantation. In press. doi:10.1097/TP.0000000000001371

Dufrane, D., Goebbels, R.M., Saliez, A., Guiot, Y., Gianello, P. 2016. Six-month survival of microencapsulated pig islets and alginate biocompatibility in primates: proof of concept. Transplantation. 81, 1345-1353.

Ekser, B., Ezzelarab, M., Hara, H., et al. 2012. Clinical xenotransplantation: the next medical revolution? Lancet. 379, 672-683.

Groth, C.G., Korsgren, O., Tibell, A., et al. 1994, Transplantation of porcine fetal pancreas to diabetic patients. Lancet. 344, 1402-1404.

Markmann, J.F., Barlett, S.T., Johnson, P., et al. 2016. Executive summary of IPITA-TTS opinion leaders report on the future of B-cell replacement. Transplantation. 100, e25-e31.

Matsumoto, S., Tan, P., Baker, J., et al. 2014. Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant. Proc. 46, 1992-1995.
Matsumoto, S., Abalovich, A., Wechsler, C., Wynyard, S., Elliott, R.B., 2016. Clinical benefit of islet xenotransplantation for the treatment of type 1 diabetes. EBioMedicine http://dx.doi.org/10.1016/j.ebiom.2016.08.034

Nagaraju, S., Bottino, R., Wijkstrom, M., Trucco, M., Cooper, D.K.C. 2015. Islet xenotransplantation: what is the optimal age of the islet-source pig? Xenotransplantation. 22, 7-19.

Park, C.G., Bottino, R., Hawthorne, W.J. 2015. Current status of islet xenotransplantation. Int. J. Surg. 23, 261-266.

van der Windt, D.J., Bottino, R., Kumar, G., et al. 2012. Clinical islet xenotransplantation: how close are we? Diabetes. 61, 3046-3055.